Chemists at the University of California, Riverside, have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer. Named TIR-199, the compound targets the "proteasome," a cellular complex in kidney cancer cells, similar to the way the drug bortezomib, approved by the Food and Drug Administration, targets the proteasome in multiple myeloma cells, a cancer coming from bone marrow. The development of TIR-199 was announced Feb. 19, 2013, in Dubai.
Fuente : http://www.eurekalert.org/pub_releases/2013-02/uoc...
Fuente : http://www.eurekalert.org/pub_releases/2013-02/uoc...